Cautions Clause Samples

Cautions. This hot air gun can produce up to 1050° F of flameless heat at the nozzle. Do not direct airstream at clothing, hair or other body parts. Do not use as a hair dryer.

Cautions. ❏ Should any discrepancy exist between the contents of this document and the provisions of the "Master Contract" or "Specifications," the latter shall take precedence over the former. ❏ We shall not be responsible for any troubles that might occur from the application of this document by customer either to a machine other than this product, or to a drive circuit or other device that is the industrial property of a third party. ❏ No part of this document may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of ▇▇▇▇▇ ▇▇▇▇▇ Corporation. ❏ The contents of this document are subject to change without notice. Please contact us for the latest information. ❏ While every precaution has been taken in the preparation of this document, Seiko Epson Corporation assumes no responsibility for errors or omissions. ❏ Neither is any liability assumed for damages resulting from the use of the information contained herein.

Cautions. Ensure that the card being presented is an actual Credit Card and not a Bank Card. Bank Cards are not Credit cards and should not be accepted. Bank cards are easily differentiated from Credit Cards because:

Cautions. 9.1 We understand that there are no guarantees that we will successfully resolve our differences by using the Collaborative Process. 9.2 We understand that the Process cannot eliminate concerns about the disharmony, distrust, and irreconcilable differences that have led to our current conflict or dispute. We understand that the Collaborative Process is not designed to address therapeutic or mental health issues. When these or other non-legal issues arise, we understand that the Collaborative Team members may deem it appropriate to refer either or both of us to experts or other professionals who are not part of the Collaborative Team and have not participated in the Collaborative Process. 9.3 We understand that until the Collaborative Process concludes, we are each voluntarily agreeing not to exercise our rights to engage in litigation, court hearings, and the formal discovery procedures described in Section 2.6. 9.4 We understand that by electing to forgo formal discovery in favor of voluntary informal disclosure of information related to the Matter, even with a representation or warranty of full and complete disclosure, we may be doing so at our own peril. 9.5 We understand that in the Collaborative Process each of us is expected to assert our own interests and that therefore we should not lapse into a false sense of security in the belief that the other participants in the Process will adequately assert our own interests without our personal participation. 9.6 We understand that there may be statutes of limitations or statutes with timing restrictions applicable to our respective legal rights, claims, and causes of action, and we acknowledge that we have been advised to seek the advice of our Collaborative Process lawyers or other lawyers about those matters. We understand that these circumstances may present a reason for beginning a court proceeding by our agreement even while our Collaborative Process Matter is in progress. 9.7 We understand that the Collaborative Process is voluntary and, despite our best efforts, we may not reach a mutually acceptable settlement. We also understand that either of us may become unwilling or unable to engage in necessary discussions, and that either of us may terminate the Collaborative Process at any time, and with or without cause. In any of those circumstances, the Collaborative Process would end, both Collaborative Process lawyers and their firms, the Collaborative Team and other professionals who participated in t...

Cautions. The captions or headings in this Agreement are for convenience only and in no way define, limit or describe the scope or intent of any provisions or sections of this Agreement.

Cautions. If party A is a corporate body, signature from a legal representative or authorized representative and common seal from the corporate are required to confirm; if party A is not a corporate body, signature from the person in charge or authorized representative and common seal from the corporate are required to confirm.

Cautions. The chronological age at the beginning of therapy should be treatment for girls who have started puberty before the age of 9 years and for boys before the age of 10 years. In girls initial ovarian stimulation at treatment initiation, followed by the treatment-induced oestrogen withdrawal, may lead, in the first month, to vaginal bleeding of mild or moderate intensity. After completing the therapy, development of puberty characteristics will occur. Information with regards to future fertility is still limited. In most girls menses will start on average one year after ending the therapy, which in most cases is regular. Bone mineral density may decrease during GnRH analogue therapy for central precocious puberty. However, after cessation of treatment subsequent bone mass accrual is preserved and peak bone mass in late adolescence does not seem to be affected by treatment. Slipped capital femoral epiphysis can be seen after withdrawal of GnRH analogue The suggested theory is that the low concentrations of estrogen during treatment with GnRH analogues weakens the epiphysial plate. The increase in growth velocity after stopping the treatment subsequently results in a reduction of the shearing force needed for displacement of the epiphysis. The treatment of children with progressive brain tumours should follow a careful individual appraisal of the risks and benefits. Pseudo-precocious puberty (gonadal or adrenal tumour or hyperplasia) and gonadotropin-independent precocious puberty (testicular toxicosis, familial Leydig cell hyperplasia) should be precluded. Allergic and anaphylactic reactions have been reported in adults and children. These include both local site reactions and systemic symptoms. The pathogenesis could not be elucidated. A higher reporting rate was seen in children. Contra-indications: None Side effects: Mild or moderate vaginal bleeding may occur in girls in the first month of treatment. Concurrent use of cyproterone acetate for the first 2 weeks can minimise the risk of vaginal bleeding. Other common adverse effects are injection site reactions and arthralgia. Triptorelin does not have black triangle (▼) status. All serious suspected adverse reactions (even well recognised or causal link uncertain) should be reported to the MHRA. Drug interactions (see also above under cautions): When triptorelin is co-administered with drugs affecting pituitary secretion of gonadotrophins, caution should be given and it is recommended that the patient's hormo...

Cautions. Elderly persons may be more sensitive to the psychoactive/CNS effects, and postural hypotensive effects of the medication, especially those with dementia. 1. The resident has a diagnosis of HIV+ or AIDS related cachexia, which has been documented by laboratory studies; OR

Cautions. ❖ Your message, as well as my response, will become part of your Clinical Records. ❖ Your communication is not secure. If you prefer and your system allows, I can help you use encryption to better protect your confidentiality.